Details for New Drug Application (NDA): 201739

✉ Email this page to a colleague

NDA 201739 describes AUVI-Q, which is a drug marketed by Kaleo Inc and is included in one NDA. It is available from three suppliers. There are eighteen patents protecting this drug. Additional details are available on the AUVI-Q profile page.

The generic ingredient in AUVI-Q is epinephrine. There are twenty-one drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the epinephrine profile page.

Summary for 201739

Tradename:	AUVI-Q
Applicant:	Kaleo Inc
Ingredient:	epinephrine
Patents:	18

Pharmacology for NDA: 201739

Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists

Medical Subject Heading (MeSH) Categories for 201739

Adrenergic alpha-Agonists
Adrenergic beta-Agonists
Bronchodilator Agents
Mydriatics
Sympathomimetics
Vasoconstrictor Agents

Suppliers and Packaging for NDA: 201739

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739	NDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1320	51662-1320-1	.3 mL in 1 DOSE PACK (51662-1320-1)
AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739	NDA	HF Acquisition Co LLC, DBA HealthFirst	51662-1320	51662-1320-2	2 DOSE PACK in 1 CARTON (51662-1320-2) / .3 mL in 1 DOSE PACK

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS			Strength	EQ 0.3MG/DELIVERY
Approval Date:	Aug 10, 2012	TE:	BX	RLD:	Yes
Patent:	⤷ Subscribe	Patent Expiration:	Nov 23, 2024	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	⤷ Subscribe	Patent Expiration:	Apr 30, 2025	Product Flag?	Y	Substance Flag?		Delist Request?
Patent:	⤷ Subscribe	Patent Expiration:	Nov 23, 2024	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 201739

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Kaleo Inc	AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739-002	Aug 10, 2012	⤷ Subscribe	⤷ Subscribe
Kaleo Inc	AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739-001	Aug 10, 2012	⤷ Subscribe	⤷ Subscribe
Kaleo Inc	AUVI-Q	epinephrine	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	201739-001	Aug 10, 2012	⤷ Subscribe	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.